Cargando…
Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines
BACKGROUND: The anti-leukemic mechanism of homoharringtonine (HHT) differs from that of IM, and HHT is one of the most useful agents for use in patients with IM resistance or intolerance. The Bcl-6/p53 pathway has been shown to regulate the sensitivity of tumor cells to antitumor drugs. We tested wh...
Autores principales: | Wang, Qian, Ding, Wei, Ding, Yihan, Ma, Jingjing, Qian, Zhaoye, Shao, Jingxian, Li, Yufeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514933/ https://www.ncbi.nlm.nih.gov/pubmed/28410239 http://dx.doi.org/10.18632/oncotarget.16731 |
Ejemplares similares
-
Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX
por: Wu, Jingjing, et al.
Publicado: (2019) -
Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
por: Wei, Wenwen, et al.
Publicado: (2022) -
Synergistic Lethality Effects of Apatinib and Homoharringtonine in Acute Myeloid Leukemia
por: Shi, Yuanfei, et al.
Publicado: (2022) -
Synergistic cytotoxicity of homoharringtonine and etoposide in acute myeloid leukemia cells involves disrupted antioxidant defense
por: Zhang, Jingjing, et al.
Publicado: (2019) -
Homoharringtonine and omacetaxine for myeloid hematological malignancies
por: Lü, Shuqing, et al.
Publicado: (2014)